GenoType® MTBDRplus assay detection of drug-resistant tuberculosis in routine practice in Korea

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 1, 2013, Pages

  Lyu, J ^a   Kim, M N ^b   Song, J W ^b   Choi, C M ^b   Oh, Y M ^b   Lee, S D ^b   Kim, W S ^b   Kim, D S ^b   Shim, Tae Sun ^b  

^a Inje University College of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

Line probe assay; Multidrug resistant; Sensitivity and specificity; Tuberculosis

Indexed keywords

ISONIAZID; RIFAMPICIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GENOTYPE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; PERFORMANCE; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; SOUTH KOREA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BACTERIOLOGICAL TECHNIQUES; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84871244077     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0197     Document Type: Article

References (17)

1. Stop TB Partnership, World Health Organization. Global Plan to Stop TB, 2006-2015. WHO/HTB/STB/2006. Geneva, Switzerland: WHO, 2006.
2. Drobniewski F A, Hoffner S, Rüsch-Gerdes S, Skenders G, Thomsen V. Recommended standards for modern tuberculosis laboratory services in Europe. Eur Respir J 2006; 28: 903-909. (Pubitemid 46331956)
3. Bai G-H, Park Y-K, Choi Y-W, et al. Trend of anti-tuberculosis drug resistance in Korea, 1994-2004. Int J Tuberc Lung Dis 2007; 11: 571-576. (Pubitemid 46732647)
4. Brossier F, Veziris N, Jarlier V, Sougakoff W. Performance of MTBDR plus for detecting high/low levels of Mycobacterium tuberculosis resistance to isoniazid. Int J Tuberc Lung Dis 2009; 13: 260-265.
5. Piersimoni C, Olivieri A, Benacchio L, Scarparo C. Current perspectives on drug susceptibility testing of Mycobacterium tuberculosis complex: the automated nonradiometric systems. J Clin Microbiol 2006; 44: 20-28. (Pubitemid 43100573)
6. Hillemann D, Rüsch-Gerdes S, Richter E. Application of the Genotype® MTBDR assay directly on sputum specimens. Int J Tuberc Lung Dis 2006; 10: 1057-1059. (Pubitemid 44378986)
7. Hillemann D, Rüsch-Gerdes S, Richter E. Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2007; 45: 2635-2640. (Pubitemid 47295497)
8. Ling D I, Zwerling A A, Pai M. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J 2008; 32: 1165-1174.
9. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. 2011 update. WHO/HTM/TB/2011.6. Geneva, Switzerland: WHO, 2011.
10. World Health Organization. Policy statement. Molecular line-probe assays for rapid secreening of patients at risk of multidrug resistant tuberculosis (MDR-TB). Geneva, Switzerland: WHO, 2008.
11. Park J S. Korean guidelines for tuberculosis. Seoul, Korea: Joint Committee for the Development of Korean Guidelines for Tuberculosis, Korea Center for Disease Control and Prevention, 2011.
12. Hain Lifescience. GenoType® MTBDRplus product insert. Version 1. Nehren, Germany: Hain Lifescience, 2007.
13. Boehme C C, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363: 1005-1015.
14. Scott L E, McCarthy K, Gous N, et al. Comparison of Xpert MTB/RMP with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med 2011; 8: e1001061.
15. Smith S E, Kurbatova E V, Cavanaugh J S, Cegielski J P. Global isoniazid resistance patterns in rifampin-resistant and rifampin-susceptible tuberculosis. Int J Tuberc Lung Dis 2012; 16: 203-205.
16. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. WHO/HTM/TB/2008.402. Geneva, Switzerland: WHO, 2008.
17. Williamson D A, Roberts S A, Bower J E, et al. Clinical failures associated with rpoB mutations in phenotypically occult multi-drug-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2012; 16: 216-220.